The Weekly Roundup: June 16-20

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.

Beyond the Label: How AI Tools Such as SkinGPT Enhance Skin Care Understanding

SkinGPT by Haut.AI uses AI to visually simulate skin care results, empowering inclusive, personalized skin care and bridging clinical data with patient insight.

Data Show Up to 5-Fold Higher Mortality Risk in Patients With Generalized Pustular Psoriasis

New research reveals that early discontinuation of adjuvant immunotherapy for melanoma does not lead to worse outcomes.

Nearly Half of Patients Respond to Ritlecitinib for Alopecia Areata, With Most Sustaining Results

Subgroups more likely to respond included women and those with shorter-duration, less-extensive hair loss.

SLIDESHOW: Recent Data from LEO Pharma on Chronic Hand Eczema

Global studies from LEO Pharma highlight the diagnostic gaps, quality-of-life burdens, and treatment landscape for patients with CHE.

A Clinician’s Perspective of RAD 2025: Part 2

At RAD 2025, Maureen Offiah, MD, reflected on the sessions she felt were the most impactful as an attendee.

Q&A: Peter Lio, MD, on Safety in Pediatric AD Management and the Promise of Precision Medicine

Discover insights from Peter Lio, MD, on precision medicine in pediatric atopic dermatitis and the promising role of ruxolitinib at the RAD 2025 Conference.

Oral Ritlecitinib Plus nbUV-B Accelerates Repigmentation in Nonsegmental Vitiligo

Discover promising advancements in vitiligo treatments, including innovative therapies and combination approaches that enhance skin repigmentation and improve patient quality of life.

Investigating Roflumilast 0.05% Cream for Infant AD with Mercedes E. Gonzalez, MD

Mercedes Gonzalez, MD, discusses the promising INTEGUMENT-INFANT trial, exploring a new non-steroidal treatment for infants with atopic dermatitis.

Christina Feser, DO, Shares Therapeutic Advances in Hidradenitis Suppurativa From SCALE 2025

At SCALE 2025, Christina Feser, DO, FAAD, FAOCD, spotlighted the rapidly expanding pipeline of diverse therapies for patients with HS.

Clinical Pearls from the 2025 Fall Clinical PA/NP Meeting: Day 2

Jamie Restivo, MPAS, PA-C, shares her key takeaways from the second day of the recent Fall Clinical PA/NP Conference in Orlando, Florida.

Recap: 2025 Revolutionizing Atopic Dermatitis Conference

Catch up on all updates and advancements shared at this year's Revolutionizing Atopic Dermatitis (RAD) Conference in Nashville, Tennessee.

Journal Digest: June 18, 2025

This review of the latest dermatologic studies includes insights into differences in vitamin D levels in rosacea versus healthy individuals, psychosocial determinants and atopic dermatitis outcomes, and more.

DecisionDx®-SCC Informs Adjuvant Radiation Therapy Treatment Decisions for Patients with Cutaneous Squamous Cell Carcinoma

In a newly validated utility, the DecisionDx-SCC test can help identify patients with cutaneous squamous cell carcinoma (cSCC) likely to benefit from adjuvant radiation therapy (ART).

Inside IL-17 Inhibitors Advancing Psoriasis Care

Explore the latest insights on IL-17 inhibitors for psoriasis, highlighting their mechanisms, real-world benefits, and future treatment strategies.

German Study Explores the Emotional Impact of Work-Related CHE

A study reveals the significant emotional burden of work-related chronic hand eczema, highlighting the need for tailored psychological support for affected patients.

Shifting the Paradigm in Infant Atopic Dermatitis Treatment with Roflumilast

Pediatric dermatologist Mercedes E. Gonzalez, MD, discusses roflumilast's promise as a safe, non-steroidal treatment for atopic dermatitis in infants.

Inclusive Language in Dermatology May Improve LGBTQ+ Patient Outcomes and Data Accuracy, Study Finds

LGBTQ+-inclusive language in dermatology enhances patient care, addresses health barriers, and improves outcomes for transgender individuals facing acne challenges.

Both Upadacitinib and Abrocitinib Demonstrate Real-World Efficacy in AD Patients After 1 Year

A real-world study shows the effectiveness of upadacitinib and abrocitinib for moderate-to-severe atopic dermatitis after 52 weeks of treatment.

Ink to Impact: A Laser-Focused Mission in Justice and Dermatology

UCSD's Clean Slate Program empowers medical students through hands-on experience in tattoo removal, enhancing community health and social justice initiatives.

Social Media Significantly Influences Attitudes, Behaviors Toward Skin Health

Researchers conducted a systematic review to summarize research that has addressed social media’s impact on skin health promotion activities.

VALIANT Survey Shows High Rates of Depression in Patients with Vitiligo

The VALIANT survey uncovers alarming depression rates in vitiligo patients, highlighting the urgent need for improved mental health screenings and interventions.

Upadacitinib Induces Long-Term Remission in Refractory Bullous Pemphigoid: A Case Report

Upadacitinib’s targeted inhibition of JAK1 offers a novel strategy for managing bullous pemphigoid, and in rare, treatment-resistant cases, may induce sustained remission following immune modulation.

Q&A Part 1: Reviewing the Significance of Lebrikizumab for Patients With Skin of Color, With Anabela Cardoso, MD

Anabela Cardoso, MD, shares data from the phase 3b ADmirable trial—the first study to evaluate the safety and efficacy of lebrikizumab in patients with moderate to severe AD and pigmented skin.

FDA Approves Dupilumab, First and Only Targeted Medicine for Bullous Pemphigoid

Dupilumab gains FDA approval as the first targeted therapy for bullous pemphigoid, offering hope for effective treatment and improved patient outcomes.

Clinical Pearls from the 2025 Fall Clinical PA/NP Meeting: Day 3

Jamie Restivo, MPAS, PA-C, shares her key takeaways from the final day of the recent Fall Clinical PA/NP Conference in Orlando, Florida.

Nail Trends That Challenge Clinical Diagnosis

Trendy manicures like Russian nails and 3D art may complicate diagnosis or cause damage, making them important for dermatologists to recognize.

HS Uncovered: Global Survey Highlights Patient Perspectives and Psychosocial Impact

A global survey reveals the significant psychosocial and financial burdens of hidradenitis suppurativa, highlighting the need for improved patient care and treatment options.